Keyphrases
Metastatic NSCLC
100%
Oligometastatic Disease
61%
Radical Treatment
50%
Immune Checkpoint Inhibitors
50%
Survival Outcomes
50%
Clinical Application
50%
Predictive Biomarker
50%
Prognostic Biomarker
50%
Prognostic Role
25%
Predictive Role
25%
Non-small Cell Lung Cancer (NSCLC)
24%
Confidence Interval
23%
Hazard Ratio
23%
Treatment Strategy
20%
Chemotherapy-only
19%
Liquid Imaging
12%
Locoregional Treatment
12%
Heterogeneous Studies
12%
Image Features
12%
Heterogeneous Patients
12%
Tissue-based
12%
Early Development
12%
Longitudinal Follow-up
12%
Patient Demographics
12%
Liquid Biopsy
12%
Metastatic Disease
12%
Disease Outcome
12%
Tumor Tissue
12%
Outcome Prediction
12%
Multiple Tissues
12%
INIS
patients
61%
diseases
52%
applications
50%
biological markers
50%
chemotherapy
50%
hazards
42%
data
19%
tissues
18%
proceedings
14%
comparative evaluations
14%
metastases
13%
cancer
13%
populations
12%
tumors
12%
organs
7%
multivariate analysis
7%
liquids
6%
tools
6%
biopsy
6%
inclusions
6%
clinical trials
6%
evaluation
6%
validation
6%
licenses
6%
values
6%
lungs
6%
reviews
6%
Medicine and Dentistry
Non-Small Cell Lung Cancer
100%
Biological Marker
50%
Immune Checkpoint Inhibitor
50%
Diseases
43%
Hazard Ratio
37%
Metastatic Carcinoma
12%
Overall Survival
12%
Systemic Therapy
12%
Patient Population
6%
Tumor Imaging
6%
Clinical Trial
6%
Population Research
6%
Liquid Biopsy
6%
Neoplasm
6%
Patient Selection
6%
Lung Cancer
6%
Tumor Microenvironment
6%
Cancer Treatment
6%
Multivariate Analysis
6%
Subgroup Analysis
6%
Retrospective Study
6%
Progression Free Survival
6%
